* Terns Pharmaceuticals Inc TERN.OQ reported a quarterly
adjusted loss of 30 cents per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of -31 cents. The mean expectation of
nine analysts for the quarter was for a loss of 34 cents per
share. Wall Street expected results to range from -41 cents
to -29 cents per share.
* Reported revenue was zero; analysts expected zero.
* Terns Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 30 cents.
* The company reported a quarterly loss of $22.37 million.
* Terns Pharmaceuticals Inc shares had fallen by 15.2% this
quarter and lost 14.3% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 2.2%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Terns
Pharmaceuticals Inc is $15.00
This summary was machine generated from LSEG data May 13 at
02:34 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.34 -0.30 Beat
Dec. 31 2023 -0.29 -0.29 Met
Sep. 30 2023 -0.31 -0.42 Missed
Jun. 30 2023 -0.34 -0.25 Beat